Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$875.0K-37.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Zackary S. Irani
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 50
- Beta
- 0.31
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -11.92
Financials
Revenue
$875.0K-37.9%Net Income
$-1.15MEBITDA
$-1.42MFree Cash Flow
$-949.0KEPS (diluted)
$-0.37Shares Outstanding (diluted)
3.07M-62.4%Operating Expenses
$1.46MCash & Debt
$1.31MReturn of Capital
$0.00Revenue by Segment (annual)
$7.20MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $4.45M | $-3.77M | $-1.30 |
| 2025 | $5.31M | $-4.97M | $-2.16 |
| 2024 | $5.42M | $-5.98M | $-0.36 |
| 2023 | $5.34M | $-7.14M | $-0.50 |
| 2022 | $18.87M | $-4.53M | $-0.36 |
| 2021 | $7.20M | $-7.45M | $-0.54 |
| 2020 | $6.69M | $-2.34M | $-0.23 |
| 2019 | $5.20M | $-2.39M | $-0.26 |
| 2018 | $5.56M | $-1.47M | $-0.17 |
| 2017 | $5.79M | $-908.6K | $-0.11 |
| 2016 | $5.14M | $-1.50M | $-0.20 |
| 2015 | $4.96M | $-331.4K | $-0.04 |
| 2014 | $5.12M | $-215.7K | $-0.03 |
| 2013 | $6.47M | $537.0K | $0.08 |
Valuation
BMRAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
Biomerica Reports First Quarter Fiscal 2027 Financial Results IRVINE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) ("Biomerica" or the "Company") today reported financial results for the first quarter of fiscal 2027, ended August 31, 2026.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Biomerica Reports Fiscal 2026 Year-End Financial Results IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2026 (“Fiscal 2026”).
View source ↗ - Newsglobenewswire.com·50d ago·Negative
Biomerica Announces $2.23 Million Financing IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (“Biomerica” or the “Company”), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the Company's common stock at a price of $1.60 per share, expected to provide approximately $2.23 million in gross proc…
View source ↗
Earnings
Wed, Oct 21(in 4 days)
Consensus estimate $-1.20 per share
Typical surprise -150.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 31$-0.38 vs $-1.20beat
- Mon, Apr 13$-0.44 vs $-1.20beat
- Mon, Sep 1$-0.16 vs $0.32miss
- Mon, Apr 14$-0.48 vs $0.16miss
- Wed, Jan 15$-0.48 vs $0.32miss
Estimates and results for BMRA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BMRA officers and directors.
- Bought
- $250k
- Sold
- $81k
19 trades
6 trades
- Moatazedi Davidbought
- Chin Ericbought
- Barbieri Allenbought
- Irani Zackary S.bought
- Gary M. Huffbought
- Irani Zackary S.bought
- Irani Zackary S.bought
- Irani Zackary S.bought
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BMRA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.